DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Denosumab

Denosumab

  • STIM1 Controls Calcineurin/Akt/Mtor/NFATC2‑Mediated Osteoclastogenesis Induced by RANKL/M‑CSF

    STIM1 Controls Calcineurin/Akt/Mtor/NFATC2‑Mediated Osteoclastogenesis Induced by RANKL/M‑CSF

  • Denosumab and Anti-Angiogenetic Drug-Related Osteonecrosis of the Jaw: an Uncommon but Potentially Severe Disease

    Denosumab and Anti-Angiogenetic Drug-Related Osteonecrosis of the Jaw: an Uncommon but Potentially Severe Disease

  • Managing Osteoporosis and Joint Damage in Patients with Rheumatoid Arthritis: an Overview

    Managing Osteoporosis and Joint Damage in Patients with Rheumatoid Arthritis: an Overview

  • Denosumab

    Denosumab

  • Paracrine and Endocrine Actions of Bone—The Functions of Secretory

    Paracrine and Endocrine Actions of Bone—The Functions of Secretory

  • Denosumab, Cortical Bone and Bone Erosions in Rheumatoid Arthritis

    Denosumab, Cortical Bone and Bone Erosions in Rheumatoid Arthritis

  • Osteonecrosis of the Jaws Produced by Sunitinib

    Osteonecrosis of the Jaws Produced by Sunitinib

  • Denosumab (Prolia™, XGEVA™)

    Denosumab (Prolia™, XGEVA™)

  • Denosumab (Prolia) Is a Biologic Medication Used to Which Normally Causes Bone Turnover

    Denosumab (Prolia) Is a Biologic Medication Used to Which Normally Causes Bone Turnover

  • White Spot Lesions After Orthodontic Treatment Assessed by Clinical

    White Spot Lesions After Orthodontic Treatment Assessed by Clinical

  • The Differential Effects of Two Critical Osteoclastogenesis Stimulating Factors on Bone Biomechanics Yuyu Yuan Clemson University, Yyuan@Clemson.Edu

    The Differential Effects of Two Critical Osteoclastogenesis Stimulating Factors on Bone Biomechanics Yuyu Yuan Clemson University, [email protected]

  • Drug Repositioning: New Approaches and Future Prospects for Life-Debilitating Diseases and the COVID-19 Pandemic Outbreak

    Drug Repositioning: New Approaches and Future Prospects for Life-Debilitating Diseases and the COVID-19 Pandemic Outbreak

  • Denosumab – Osteoporosis Medical Drug Program Summary

    Denosumab – Osteoporosis Medical Drug Program Summary

  • The Role of BMP Signaling in Osteoclast Regulation

    The Role of BMP Signaling in Osteoclast Regulation

  • Denosumab: a New Therapy for Osteoporosis Editor by Candice Gehret, Pharm.D

    Denosumab: a New Therapy for Osteoporosis Editor by Candice Gehret, Pharm.D

  • New Drugs 1998

    New Drugs 1998

  • Standard Specialty PA and QL List January 2015

    Standard Specialty PA and QL List January 2015

  • Molecular Mechanisms and Clinical Management of Cancer Bone Metastasis

    Molecular Mechanisms and Clinical Management of Cancer Bone Metastasis

Top View
  • Radiographic Progression in Clinical Trials in Rheumatoid Arthritis: a Systemic Literature Review of Trials Performed by Industry
  • Medications Requiring Prior Authorization
  • Prolia, INN-Denosumab
  • The Effect of Denosumab, the Inhibitor for Receptor
  • Circular RNA Circikbkb Promotes Breast Cancer Bone Metastasis
  • (Prolia) (Rheumatoid Arthritis) – Forecast and Market Analysis to 2023
  • Colorado 4Th Tier Medication List
  • Precertification, High Dollar Medication Approvals, and Utilizing
  • NEW 2018 Specialty Drugs
  • Pharmaphacts
  • MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional
  • Neupogen, Neulasta, Zarxio, Leukine, Granix
  • Lumicera Specialty Drug List
  • Drugs Requiring Prior Authorization List
  • Prior Authorization for Medications
  • Denosumab: Recent Update in Postmenopausal Osteoporosis
  • METASTATIC RENAL CELL CARCINOMA (Case Study) Disclosures
  • Effects of Denosumab in Japanese Patients with Rheumatoid Arthritis


© 2024 Docslib.org    Feedback